Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation
Circulation · 2023
DOI: 10.1161/circulationaha.122.060002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2023. Verfasst von Leslie B Gordon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Genetics, Hasbro Children's Hospital, Providence, RI (L.B.G., W.N.). Hauptthemen laut MEDLINE: Progeria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS.
Abstract (Originalsprache)
Background
Hutchinson-Gilford progeria syndrome (HGPS) is an ultrarare, fatal, premature aging disease caused by a toxic protein called progerin. Circulating progerin has not been previously detected, precluding research using readily available biological samples. This study aimed to develop a plasma progerin assay to evaluate progerin’s quantity, response to progerin-targeted therapy, and relationship to patient survival.
Methods
Biological samples were collected by The Progeria Research Foundation Cell and Tissue Bank from a non-HGPS cohort cross-sectionally and a HGPS cohort longitudinally. HGPS donations occurred at baseline and intermittently while treated with farnesylation inhibitors lonafarnib±pravastatin and zoledronate, within 3 sequential open-label clinical trials at Boston Children’s Hospital totaling >10 years of treatment. An ultrasensitive single-molecule counting progerin immunoassay was developed with prespecified performance parameters. Intra- and interpatient group statistics were descriptive. The relationship between progerin and survival was assessed by using joint modeling with time-dependent slopes parameterization.
Results
The assay’s dynamic detection range was 59 to 30 000 pg/mL ( R 2 =0.9987). There was no lamin A cross-reactivity. Mean plasma progerin in non-HGPS participants (n=69; 39 male, 30 female; age, 0.2–71.3 years) was 351±251 pg/mL, and in drug-naive participants with HGPS (n=74; 37 female, 37 male; age, 2.1–17.5 years) was 33 261±12 346 pg/mL, reflecting a 95-fold increase in affected children ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Genetics, Hasbro Children's Hospital, Providence, RI (L.B.G., W.N.).
- Warren Alpert Medical School of Brown University, Providence, RI (L.B.G.).
- Department of Anesthesiology, Critical Care and Pain Medicine (L.B.G., M.E.K.), Boston Children's Hospital and Harvard Medical School, Boston, MA.
- The Progeria Research Foundation, Peabody, MA (L.B.G., K.T.).
- EMD Millipore (S.H., R.G.).
- Department of Biostatistics (J.L., J.M.M.), Boston University, MA.
ORCID-Profile: Leslie B Gordon, Mark W Kieran, Monica E Kleinman
Förderung
- FDA HHS
Zitieren
APA
Gordon, L. B., Norris, W., Hamren, S., Goodson, R., LeClair, J., Massaro, J., Lyass, A., D'Agostino, R. B., Tuminelli, K., Kieran, M. W., & Kleinman, M. E. (2023). Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Circulation. https://doi.org/10.1161/circulationaha.122.060002
Vancouver
Gordon LB, Norris W, Hamren S, Goodson R, LeClair J, Massaro J, et al. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Circulation. 2023. doi:10.1161/circulationaha.122.060002
BibTeX
@article{Gordon2023,
author = {Gordon, Leslie B and Norris, Wendy and Hamren, Sarah and Goodson, Robert and LeClair, Jessica and Massaro, Joseph and Lyass, Asya and D'Agostino, Ralph B and Tuminelli, Kelsey and Kieran, Mark W and Kleinman, Monica E},
title = {Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.122.060002}
}
EUVIMED